GU Experts Review Treatment Options, Remaining Challenges, and Future Research in Penile Cancer | OncLive

GU Experts Review Treatment Options, Remaining Challenges, and Future Research in Penile Cancer

August 31, 2020

Today, we had the pleasure of sitting down with a group of experts in genitourinary cancers from Dana-Farber Cancer Institute, Brigham and Women’s Hospital, and Moffitt Cancer Center to discuss a malignancy that is not often an everyday focus: penile cancer.

Welcome to a very special edition of OncLive® On Air. I’m your host today, Gina Columbus.

OncLive® On Air is a podcast from OncLive, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive covers every angle of oncology practice from new technology to treatment advances to important regulatory decisions.

Today, we had the pleasure of sitting down with a group of experts in genitourinary cancers from Dana-Farber Cancer Institute, Brigham and Women’s Hospital, and Moffitt Cancer Center, to discuss a malignancy that is not often an everyday focus: penile cancer.

In an effort to share some of the evolving knowledge about penile cancer, the panel took time to highlight research surrounding the overall frequency and prevalence of the disease, current survival outcomes, and available treatment options.

The conversation then turned to challenges with existing therapies, recent data that were presented at the 2020 American Urological Association Annual Meeting and 2020 ASCO Virtual Scientific Program. They also shined a light on ongoing research that has the potential to transform the paradigm.

Our episode is filled with insights from Guru Sonpavde, MD and Kent W. Mouw, MD, both of Dana-Farber Cancer Institute, Matthew Mossanen, MD, of Brigham and Women’s Hospital, Jad Chahoud, MD, and Philippe Spiess, MD of Moffitt Cancer Center.

Let’s head to this insightful OncLive On Air episode, right now.


x